Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FBP1 | P09467 | 2/20 | 0.50 |
| ▸ | UMPS | P11172 | 5/20 | 0.48 |
| ▸ | DNPH1 | O43598 | 1/20 | 0.48 |
| ▸ | HPRT1 | P00492 | 1/20 | 0.47 |
| ▸ | P2RY2 | P41231 | 2/20 | 0.45 |
| ▸ | LDHA | P00338 | 1/20 | 0.45 |
| ▸ | P2RY6 | Q15077 | 1/20 | 0.45 |
| ▸ | ATIC | P31939 | 2/20 | 0.44 |
| ▸ | GART | P22102 | 1/20 | 0.44 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.44 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19370845 | 1.00 | FBP1 (0.50) | FBP1UMPSDNPH1HPRT1P2RY2 | |
| SCHEMBL7269691 | 1.00 | FBP1 (0.50) | FBP1UMPSDNPH1HPRT1P2RY2 | |
| SCHEMBL25834288 | 0.91 | P2RY2 (0.43) | UMPSDNPH1P2RY2P2RY6 | |
| SCHEMBL11178912 | 0.79 | HPRT1 (0.53) | FBP1UMPSDNPH1HPRT1P2RY2 | |
| SCHEMBL31685403 | 0.74 | FBP1 (0.46) | FBP1UMPSDNPH1HPRT1P2RY2 | |
| SCHEMBL11758791 | 0.72 | CDA (0.62) | FBP1UMPSDNPH1HPRT1P2RY2 | |
| SCHEMBL21067752 | 0.72 | NT5E (0.30) | — | |
| SCHEMBL11755358 | 0.72 | CDA (0.62) | FBP1UMPSDNPH1HPRT1P2RY2 | |
| SCHEMBL11755974 | 0.72 | HPRT1 (0.53) | FBP1UMPSDNPH1HPRT1P2RY2 | |
| SCHEMBL11760447 | 0.72 | HPRT1 (0.53) | FBP1UMPSDNPH1HPRT1P2RY2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3681504-B1 | METHODS OF DETECTION USING X-RAY FLUORESCENCE | ICAGEN INC (US) | 2023-08-23 | — | — | EP | disclosed |
| US-11573224-B2 | Methods of detection using X-ray fluorescence | ICAGEN, LLC (US) | 2023-02-07 | — | — | US | disclosed |
| US-11446398-B2 | Regulated biocircuit systems | OBSIDIAN THERAPEUTICS, INC. (US) | 2022-09-20 | — | — | US | disclosed |
| US-20210254056-A1 | IDENTIFICATION AND TARGETED MODULATION OF GENE SIGNALING NETWORKS | CAMP4 THERAPEUTICS CORPORATION | 2021-08-19 | — | — | US | disclosed |
| US-10877035-B2 | Advanced drug development and manufacturing | ICAGEN, LLC (US) | 2020-12-29 | — | — | US | disclosed |
| US-20200278346-A1 | METHODS OF DETECTION USING X-RAY FLUORESCENCE | ADJACENT ACQUISITION CO., LLC | 2020-09-03 | — | — | US | disclosed |
| US-20190192691-A1 | REGULATED BIOCIRCUIT SYSTEMS | OBSIDIAN THERAPEUTICS, INC. | 2019-06-27 | — | — | US | disclosed |
| US-20150309021-A1 | Advanced Drug Development and Manufacturing | LOS ALAMOS NATIONAL SECURITY, LLC | 2015-10-29 | — | — | US | disclosed |
| EP-2511844-B1 | X-ray microscope | XRPRO SCIENCES INC (US) | 2015-08-12 | — | — | EP | disclosed |
| EP-1931691-B1 | ODCASE INHIBITORS FOR THE TREATMENT OF MALARIA | UNIV HEALTH NETWORK (CA) | 2013-08-21 | — | — | EP | disclosed |
| US-8067391-B2 | ODCase inhibitors for the treatment of malaria | UNIVERSITY HEALTH NETWORK (CA) | 2011-11-29 | — | — | US | disclosed |
| US-20100087388-A1 | ODCASE INHIBITORS AS ANTI-VIRALS AND ANTIBIOTICS | KOTRA LAKSHMI P | 2010-04-08 | — | — | US | disclosed |
| US-20100056468-A1 | Pyrimidine Derivatives As Anticancer Agents | UNIVERSITY HEALTH NETWORK (CA) | 2010-03-04 | — | — | US | disclosed |
| US-20090221524-A1 | ODCASE INHIBITORS FOR THE TREATMENT OF MALARIA | UNIVERSITY HEALTH NETWORK (CA) | 2009-09-03 | — | — | US | disclosed |
| EP-2084519-A2 | ADVANCED DRUG DEVELOPMENT AND MANUFACTURING | Los Alamos National Security, LLC (US) | 2009-08-05 | — | — | EP | disclosed |
| WO-2008127291-A2 | ADVANCED DRUG DEVELOPMENT AND MANUFACTURING | LOS ALAMOS NATIONAL SECURITY, LLC (US) | 2008-10-23 | — | — | WO | disclosed |
| US-20080220441-A1 | Advanced drug development and manufacturing | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2008-09-11 | — | — | US | disclosed |
| US-20030138432-A1 | Selective cellular targeting: multifunctional delivery vehicles, multifunctional prodrugs, use as antineoplastic drugs | DRUG INNOVATION & DESIGN, INC. | 2003-07-24 | — | — | US | disclosed |
| EP-1255567-A1 | SELECTIVE CELLULAR TARGETING: MULTIFUNCTIONAL DELIVERY VEHICLES | Drug Innovation & Design, Inc. (US) | 2002-11-13 | — | — | EP | disclosed |
| WO-2001036003-A2 | SELECTIVE CELLULAR TARGETING: MULTIFUNCTIONAL DELIVERY VEHICLES | DRUG INNOVATION & DESIGN, INC. (US) | 2001-05-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090221524-A1 | ODCASE INHIBITORS FOR THE TREATMENT OF MALARIA | UMPS, UGDH, UPP1 | FBP1 50/4885UMPS 1/4885DNPH1 222/4885 |
| US-20100056468-A1 | Pyrimidine Derivatives As Anticancer Agents | DPYD, TYMP, TYMS | FBP1 95/4885UMPS 17/4885DNPH1 2623/4885 |
| US-20030138432-A1 | Selective cellular targeting: multifunctional delivery vehicles, multifunctional prodrugs, use as antineoplastic drugs | PAICS, ABCB1, ABCG2 | FBP1 1683/4885UMPS 306/4885DNPH1 210/4885 |
| US-20100087388-A1 | ODCASE INHIBITORS AS ANTI-VIRALS AND ANTIBIOTICS | ITPA, DUT, MAOA | FBP1 12/4885UMPS 10/4885DNPH1 1002/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.